Logo of FSD Pharma. Click to go to a Home page

Investor Relations

Latest Releases

VIEW ALL RELEASES

Stock Quote

NASDAQ: HUGE
CHANGE
VOLUME
52 WEEKS
-
DAY
-
Minimum 20 minute delay.
VIEW STOCK CHART

November, 2023

Latest Investor Presentation

FSD Pharma, Inc.

DOWNLOAD PDF

November 24, 2024

Goldman Small Cap Research Coverage Initiation

Our Pick of the Year; Major Catalysts and Valuation Drivers Ahead and a $4.60 Price Target

DOWNLOAD PDF

September 7, 2023

Singular Research Coverage Initiation

Targeting Multi-Billion Dollar Markets with Unmet Needs; Initiate with a Buy-Venture rating and a $6.00 price target

DOWNLOAD PDF

Latest SEC Filings

VIEW ALL FILINGS

Company Structure

Our leadership consists of a passionate management team with diverse industry knowledge, committed to science, therapeutic drug discovery and development.

Board of Directors

VIEW TEAM

Expert Research & Clinical Team

VIEW TEAM

Management Team

VIEW TEAM

Regulatory Advisory Board

VIEW TEAM

Competitive Advantage / Value Proposition

  • World-Class Pipeline

    • Neurodegenerative and neuropsychiatric disease, multi-billion dollar markets, unmet need, decades of research de-risk our drugs
    • Lucid-MS: New Chemical Entity for Multiple Sclerosis, pre-clinical research re-established use of paralyzed rear legs in MS mouse model, research published in peer-reviewed journals. FSD Pharma has finished dosing in phase-1 for Lucid-MS (Lucid-21-302) for first in-class human safety and tolerability investigation
    • IP Estate: FSD Pharma has rights to patent families licensed on an exclusive basis
  • Elite Team

    • FSD Pharma’s flagship subsidiary led by Dr. Lakshmi Kotra, the recipient of the Julia Levy Award and a senior scientist at the Krembil Brain Institute, as well as the world-renowned University Health Network (UHN).
    • FSD Pharma has a world class team working full-time on pipeline development, with backgrounds at the FDA, major pharmaceuticals firms, and esteemed universities.
    • FSD Pharma team includes Julia Levy Award recipient, a distinguished award that has only been awarded to 8 recipients since its inception in 2005 (no other company can make this claim)
  • Strong Cash Position

    • Cash enough to carry operations
    • No dilution on horizon for shareholders
  • Solid Cap Table / Insider Ownership

    • Only 39.3 million shares issued
    • Share repurchase plan completed for 2022, approximately 2 million shares returned to treasury in 2022. Another 2 million shares returned to treasury in 2023
    • Co-founders, directors and other insiders frequently buying shares since start of 2022 and continue to accumulate shares. This can be verified by checking the SEDI filings

*Data current as of 16th July, 2023

Industry Classifications

Sector

Healthcare

Industry

Drug Manufacturers

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical and Medicine Industry (3741)

Share by: